Talaris Therapeutics Analysis
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
Talaris Therapeutics is overvalued with Real Value of 2.42 and Hype Value of 2.98. The main objective of Talaris Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Talaris Therapeutics is worth, separate from its market price. There are two main types of Talaris Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Talaris Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Talaris Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Talaris Stock trading window is adjusted to America/New York timezone.
Talaris |
Talaris Stock Analysis Notes
About 78.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.28. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Talaris Therapeutics recorded a loss per share of 1.97. The entity last dividend was issued on the 19th of October 2023. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people. To find out more about Talaris Therapeutics contact JD LLB at 502 398 9250 or learn more at https://talaristx.com.Talaris Therapeutics Investment Alerts
| Talaris Therapeutics is not yet fully synchronised with the market data | |
| Talaris Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (73.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Talaris Therapeutics currently holds about 207.11 M in cash with (60.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are owned by institutional investors |
Talaris Therapeutics Upcoming and Recent Events
| 9th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Talaris Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 125.73 M.Talaris Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Talaris Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Talaris Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Talaris Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Talaris Therapeutics Outstanding Bonds
Talaris Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Talaris Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Talaris bonds can be classified according to their maturity, which is the date when Talaris Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Talaris Therapeutics Predictive Daily Indicators
Talaris Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Talaris Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Talaris Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Talaris Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Talaris shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Talaris Therapeutics. By using and applying Talaris Stock analysis, traders can create a robust methodology for identifying Talaris entry and exit points for their positions.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Talaris Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |